Biofil Chemicals & Pharmaceuticals Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Biofil Chemicals and Pharmaceuticals' board has approved the financial results for the quarter ended June 30, 2025. Net profit surged to ₹2.41 Cr, significantly up from ₹0.17 Cr last year, primarily due to the disposal of an undertaking.

The board also approved re-appointing Independent Directors Ashok Kumar Ramawat and Satish Beohar. Ketan Shah's designation changed from Whole-Time Director to Chairman and Managing Director for three years, subject to shareholder approval. A new Finance Committee was constituted, and the registered office will shift within Indore from September 1, 2025. The 40th Annual General Meeting will be held on September 27, 2025.